'On standalone basis

Quarter ended March 2025 compared with Quarter ended March 2024.

Net sales (including other operating income) of Supriya Lifescience has increased 16.39% to Rs 184.11 crore.  Operating profit margin has jumped from 35.08% to 36.71%, leading to 21.79% rise in operating profit to Rs 67.58 crore.  Raw material cost as a % of total sales (net of stock adjustments) increased from 32.62% to 43.99%.   Employee cost decreased from 11.56% to 9.09%.   Other expenses fell from 18.39% to 17.65%.   

Other income up 36.07% to Rs 2.98 crore.  PBIDT rose 22.33% to Rs 70.56 crore.  Provision for interest fell 30% to Rs 0.42 crore.  Loan funds declined from Rs 5.49 crore as of 31 March 2024 to Rs 5.38 crore as of 31 March 2025.  Inventories rose to Rs 118.35 crore as of 31 March 2025 from Rs 85.25 crore as of 31 March 2024.  Sundry debtors were higher at Rs 134.36 crore as of 31 March 2025 compared to Rs 111.68 crore as of 31 March 2024.  Cash and ba...

• 

  (15-Jul-2025)

  ICICI Prudential Life Insurance Company

  Profit improves 34%, VNB Margin improves in Q1FY2026
• 

  (15-Jul-2025)

  Swaraj Engines

  PAT increased 15.7%
• 

  (12-Jul-2025)

  Elecon Engineering Company

  Net up 139% inflated by higher one off income
• 

  (12-Jul-2025)

  Avenue Supermarts

  Revenue up 16.3% YoY to Rs 16359.7 crore, Net profit flat at Rs 773 crore in Q1FY2026